Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × icotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Lung Neoplasms 4 Brain Neoplasms 4 Esophageal Neoplasms 2 EGF-R Positive Non-Small Cell Lung Cancer 2 Adenocarcinoma of Lung 2 Squamous Cell Carcinoma of Lung 1 Plasma EGFR Mutation-positive Lung Cancer 1 Non-small Cell Lung Cancer Metastatic 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Drug-Related Side Effects and Adverse Reactions 1 Bronchial Neoplasms 1 Breast Neoplasms 1

Interventions

Bevacizumab 47 Gemcitabine 46 Cyclophosphamide 43 Carboplatin 37 Docetaxel 36 Fluorouracil 33 Cisplatin 33 Paclitaxel 31 pembrolizumab 30 Oxaliplatin 27 Radiotherapy 25 Irinotecan 25 Capecitabine 25 Leucovorin 23 Dexamethasone 23 Cetuximab 21 Nivolumab 20 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 14 Lapatinib 14 trametinib 13 fludarabine 13 Sorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03736837 2021-03-15

ALTER-L004

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡